1697P Phase II Randomized Double-Blind Trial of Axitinib (axi) +/- PF 04518600, an OX40 Antibody (PFOX) after PD1/PDL1 Antibody (IO) Therapy (tx) in Metastatic Renal Cell Carcinoma (mrcc): Final Analysis
Annals of Oncology(2024)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要